In a study of metastatic melanomas, there was a substantial increase in tumor-infiltrating CD4+ and CD8+ T cells after 7 days of treatment with a BRAF inhibitor (vemurafenib or dabrafenib)6. This evidence concerns the gene CD8A and neoplasm.